The Clinical Research On Treatment Of Diabetic Subclinical Atherosclerosis From "Poison"

Objective: To observe Tongluo decoction of type2diabetes (Type2DiabetesMellitus, T2DM) subclinical atherosclerosis (Atherosclerosis AS) in patients with carotidartery intima-media thickness (IMT) and interleukin-6(IL-6) the impact of explore from"poisonous" treating diabetes subclinical atherosclerosis mechanism for clinical preventionand treatment of diabetes subclinical atherosclerosis provide ideas and methods. Methods:60cases of Qi, Ecchymosis stasis subclinical atherosclerosis in patients with diabetes wererandomly divided into treatment group (30cases) and control group (30cases) and controlgroup only basic treatment, the treatment group based therapy based on the use of Tongluodecoction, six month course of treatment, the treatment two courses. Before and aftertreatment were observed in clinical symptoms and signs, IMT, IL-6changes. Results:After treatment, there are significant differences between the IMT (P<0.05), IL-6levelswere significantly different (P<0.01); treatment symptom scores between the two groupswere significantly different (P<0.05); treatment TCM syndrome group, the effective ratewas83.33%in the control group was50.00%, the treatment group than the control group.Conclusion: Tongluo Decoction can significantly improve diabetes subclinicalatherosclerosis in patients with clinical signs and symptoms as well as IMT, IL-6levels.